{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T14:55:48Z","timestamp":1767711348214,"version":"3.48.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Natural Science Foundation of Liaoning Province","award":["2023JH2\/101700078"],"award-info":[{"award-number":["2023JH2\/101700078"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82372070"],"award-info":[{"award-number":["82372070"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-04132-4","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T22:04:14Z","timestamp":1764713054000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hepatic arterial infusion chemotherapy via arterial infusion port combined with Atezolizumab and Bevacizumab for conversion therapy of advanced hepatocellular carcinoma: a case report"],"prefix":"10.1007","volume":"17","author":[{"given":"Jiaxuan","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zichun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulong","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haibo","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"4132_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"4132_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6.","journal-title":"Nat Rev Dis Primers"},{"key":"4132_CR3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3748\/wjg.v22.i1.407","volume":"22","author":"K Han","year":"2016","unstructured":"Han K, Kim JH, Ko GY, Gwon DI, Sung KB. Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: a comprehensive review. World J Gastroenterol. 2016;22:407\u201316.","journal-title":"World J Gastroenterol"},{"key":"4132_CR4","doi-asserted-by":"crossref","unstructured":"Tao Y, Song M, Zhang H, He H, Du M, Guo L, et al. Large well-differentiated hepatocellular carcinoma in patients with HBV: gadoxetic acid-enhanced MR imaging features and prognosis. Eur Radiol. 2025.","DOI":"10.1007\/s00330-025-11994-3"},{"key":"4132_CR5","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1186\/s12885-025-14543-9","volume":"25","author":"QY Chi","year":"2025","unstructured":"Chi QY, Liu QY, Wang SJ, Liu YD, Gao XD, Lin KY, et al. Lenvatinib combined with anti-PD-1 antibodies plus locoregional treatment for initial unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a multicenter real-world study. BMC Cancer. 2025;25:1162.","journal-title":"BMC Cancer"},{"key":"4132_CR6","doi-asserted-by":"publisher","first-page":"216","DOI":"10.21037\/hbsn-22-469","volume":"12","author":"DY Xie","year":"2023","unstructured":"Xie DY, Zhu K, Ren ZG, Zhou J, Fan J, Gao Q. A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2023;12:216\u201328.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"4132_CR7","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1200\/JCO.21.00608","volume":"40","author":"QJ Li","year":"2022","unstructured":"Li QJ, He MK, Chen HW, Fang WQ, Zhou YM, Xu L, et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial. J Clin Oncol. 2022;40:150\u201360.","journal-title":"J Clin Oncol"},{"key":"4132_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101130","volume":"6","author":"A Childs","year":"2024","unstructured":"Childs A, Aidoo-Micah G, Maini MK, Meyer T. Immunotherapy for hepatocellular carcinoma. JHEP Rep. 2024;6:101130.","journal-title":"JHEP Rep"},{"key":"4132_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112711","volume":"139","author":"Z Huang","year":"2024","unstructured":"Huang Z, Chen T, Li W, He W, Liu S, Wu Z, et al. Atezolizumab and bevacizumab plus transarterial chemoembolization and hepatic arterial infusion chemotherapy for patients with high tumor burden unresectable hepatocellular carcinoma: a multi-center cohort study. Int Immunopharmacol. 2024;139:112711.","journal-title":"Int Immunopharmacol"},{"key":"4132_CR10","doi-asserted-by":"publisher","first-page":"8069","DOI":"10.3748\/wjg.v27.i47.8069","volume":"27","author":"HT Zhao","year":"2021","unstructured":"Zhao HT, Cai JQ. Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma. World J Gastroenterol. 2021;27:8069\u201380.","journal-title":"World J Gastroenterol"},{"key":"4132_CR11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000514174","volume":"10","author":"M Kudo","year":"2021","unstructured":"Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, et al. Management of hepatocellular carcinoma in japan: JSH consensus statements and recommendations 2021 update. Liver Cancer. 2021;10:181\u2013223.","journal-title":"Liver Cancer"},{"key":"4132_CR12","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41392-023-01663-6","volume":"8","author":"TQ Zhang","year":"2023","unstructured":"Zhang TQ, Geng ZJ, Zuo MX, Li JB, Huang JH, Huang ZL, et al. Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study. Signal Transduct Target Ther. 2023;8:413.","journal-title":"Signal Transduct Target Ther"},{"key":"4132_CR13","doi-asserted-by":"publisher","first-page":"593","DOI":"10.3350\/cmh.2022.0391","volume":"29","author":"H Iwamoto","year":"2023","unstructured":"Iwamoto H, Shimose S, Shirono T, Niizeki T, Kawaguchi T. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity. Clin Mol Hepatol. 2023;29:593\u2013604.","journal-title":"Clin Mol Hepatol"},{"key":"4132_CR14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s12072-023-10599-6","volume":"18","author":"M Zhao","year":"2024","unstructured":"Zhao M, Guo Z, Zou YH, Li X, Yan ZP, Chen MS, et al. Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations. Hepatol Int. 2024;18:4\u201331.","journal-title":"Hepatol Int"},{"key":"4132_CR15","doi-asserted-by":"publisher","first-page":"1401882","DOI":"10.3389\/fonc.2024.1401882","volume":"14","author":"X Jiang","year":"2024","unstructured":"Jiang X, Aljbri A, Liu J, Shang L, Tian Y, Shao H. Hepatic arterial infusion chemotherapy with implantable arterial access port for advanced-stage hepatocellular carcinoma: a case report. Front Oncol. 2024;14:1401882.","journal-title":"Front Oncol"},{"key":"4132_CR16","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1159\/000524893","volume":"11","author":"K Ueshima","year":"2022","unstructured":"Ueshima K, Komemushi A, Aramaki T, Iwamoto H, Obi S, Sato Y, et al. Clinical practice guidelines for hepatic arterial infusion chemotherapy with a port system proposed by the Japanese society of interventional radiology and Japanese society of implantable port assisted treatment. Liver Cancer. 2022;11:407\u201325.","journal-title":"Liver Cancer"},{"key":"4132_CR17","doi-asserted-by":"publisher","first-page":"2416558","DOI":"10.1080\/2162402X.2024.2416558","volume":"13","author":"Y Wang","year":"2024","unstructured":"Wang Y, Zhao L, Zhang Z, Liu P. Immunogenic cell death inducers and PD-1 blockade as neoadjuvant therapy for rectal cancer. Oncoimmunology. 2024;13:2416558.","journal-title":"Oncoimmunology"},{"key":"4132_CR18","doi-asserted-by":"publisher","first-page":"2093518","DOI":"10.1080\/2162402X.2022.2093518","volume":"11","author":"P Liu","year":"2022","unstructured":"Liu P, Chen J, Zhao L, Hollebecque A, Kepp O, Zitvogel L, et al. PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer. Oncoimmunology. 2022;11:2093518.","journal-title":"Oncoimmunology"},{"key":"4132_CR19","doi-asserted-by":"publisher","first-page":"12624","DOI":"10.1038\/ncomms12624","volume":"7","author":"JJ Wallin","year":"2016","unstructured":"Wallin JJ, Bendell JC, Funke R, Sznol M, Korski K, Jones S, et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun. 2016;7:12624.","journal-title":"Nat Commun"},{"key":"4132_CR20","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","volume":"28","author":"AX Zhu","year":"2022","unstructured":"Zhu AX, Abbas AR, de Galarreta MR, Guan Y, Lu S, Koeppen H, et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med. 2022;28:1599\u2013611.","journal-title":"Nat Med"},{"key":"4132_CR21","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.2217\/fon-2020-1290","volume":"17","author":"X Liu","year":"2021","unstructured":"Liu X, Lu Y, Qin S. Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies. Future Oncol. 2021;17:2243\u201356.","journal-title":"Future Oncol"},{"key":"4132_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.929141","volume":"13","author":"Y Xin","year":"2022","unstructured":"Xin Y, Cao F, Yang H, Zhang X, Chen Y, Cao X, et al. Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Front Immunol. 2022;13:929141.","journal-title":"Front Immunol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-04132-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-04132-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-04132-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T14:53:23Z","timestamp":1767711203000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-04132-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4132"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-04132-4","relation":{},"ISSN":["2730-6011"],"issn-type":[{"type":"electronic","value":"2730-6011"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"17 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving humans were approved by The First Affiliated Hospital of China Medical University (Ethical Number: AF-SOP-07-1.2-01). The participant provided his written informed consent to participate in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report, and the accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}